Trial Steering Committee Recommends Initiation of Phase II

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Trial Steering Committee Recommends Initiation of Phase II L-DOS47 Study in Non-Small Cell Lung Cancer

AURORA, ON--(Marketwired - Apr 21, 2016) - Helix BioPharma Corp. ( TSX : HBP ) ( FRANKFURT : HBP ) ("Helix" or the "Company"), a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the recommendation by the Trial Steering Committee to initiate the Phase II component of the LDOS002 study.

" We have now determined the Phase II dose and monotherapy regimen of L-DOS47 for patients that have limited treatment options in our LDOS002 study, " said Mr. Steve Demas, the newly appointed Chief Medical Officer of Helix. Up to forty-five (45) patients will be enrolled in the Phase II open-label, non-randomized study designed to make a preliminary assessment of efficacy of L-DOS47 in patients with non-squamous non-small cell lung cancer ("NSCLC").

" Advancing our lead product candidate into Phase II is an important milestone for the Company. " said Dr. Sven Rohmann, Chief Executive Officer of Helix. "In addition, we are currently evaluating the safety of L-DOS47 in combination with pemetrexed/carboplatin in the U.S. and are planning to investigate the efficacy of L-DOS47 in combined modality with other chemo- and/or immuno-therapies."

About L-DOS47

L-DOS47 is Helix's first immunoconjugate based drug candidate in development based on the Company's novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.

About L-DOS47 clinical development

L-DOS47 is currently being clinically evaluated in two clinical studies, in Poland and in the United States, as a treatment for certain patients with NSCLC.

LDOS002 is an open-label Phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC. The study is being conducted at five Polish centers: the Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, the Military Medical Institute, the National Tuberculosis and Lung Diseases Research Institute, the Mazovian Center of Pulmonary Diseases and Tuberculosis in Otwock and the Department of Oncology, Poznan University of Medical Science.

On September 8 th , 2015, the company presented results from the ongoing LDOS002 study at the 16th World Conference on Lung Cancer held in Denver, Colorado. Results from patients enrolled in the first twelve dosing cohorts included:

  • L-DOS47 was well tolerated at dose levels studied to-date;
  • Twenty-one (21) of the 40 patients enrolled (52%) had an overall response of 'stable disease' after completion of two cycles of L-DOS47;
  • Eleven (11) of the 21 patients had a response of 'stable disease' after completing four cycles of L-DOS47;
  • One (1) patient in the 9 th dosing cohort (1.84µg/kg) was dosed for 10 cycles (approximately 7 months) without disease progression.

LDOS001 is a Phase I, open-label, dose escalation study being conducted in the U.S. at three centers: The University of Texas, M.D. Anderson Cancer Centre, Penn State Milton S. Hershey Medical Center; and University Hospitals Case Medical Center. The primary objective of the study is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed/ carboplatin.

On March 3 rd , 2016, the company reported on the progress of study LDOS001. A patient in the first dosing cohort received four cycles of L-DOS47 in combination with pemetrexed/carboplatin and an additional four cycles of L-DOS47 alone before progression of their disease. The best response reported for this patient was a 37% decrease in the sum of the diameters of target lesions identified at baseline.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Forward-Looking Statements and Risks and Uncertainties

This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the total number of patients that will be enrolled in the Polish Phase I/II clinical study and the potential generation of valuable information by such further enrollment of patients, which may be identified by words including, without limitation, "will", "may", "anticipated", and other similar expressions, are intended to provide information about management's current plans and expectations regarding the conduct of the clinical study.

 Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, (i) the inherent uncertainty involved in scientific research and drug development; (ii) the risks associated with delay or inability to complete clinical trials successfully, including that patient recruitment for the Polish Phase I/II clinical trial for L-DOS47 does not continue as scheduled or at all, that Helix's planned U.S. Phase I clinical trial for L-DOS47 proceeds in a manner and on the timelines anticipated by Helix, or at all and the long lead-times and high costs associated with obtaining regulatory approval to market any product which may result from successful completion of such trials; (iii) need to secure additional financing on terms satisfactory to Helix or at all; (iv) clinical trials that yield negative results, or results that do not justify future clinical development, including that the Polish Phase I/II clinical trial for L-DOS47 will yield negative results and that the information, if any, gained from higher dose levels in such study will not be of use in future studies; and (v) those risks and uncertainties affecting the company as more fully described in Helix's most recent Annual Report, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements.  These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

Investor Relations Helix BioPharma Corp. 3-305 Industrial Parkway South Aurora, Ontario, L4G 6X7 Tel: 905 841-2300 Email: ir@helixbiopharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 78

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 104

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 105

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 55

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 66

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 340

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 87

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 197

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading

Top 5 Most Recently Viewed Articles

Ringkjøbing Landbobank's Impressive Mid-Year Financial Update

Updated Category News Views 214

Ringkjøbing Landbobank's Financial Performance for 2025 In an exciting turn of events, Ringkjøbing Landbobank has shared its quarterly report for the first half of 2025, revealing remarkable financial outcomes that have caught the attention of analysts and stakeholders alike. Approval from Management The bank's board of directors, along with its general management, has...

Continue Reading
Mercy Medical Opens Center for Orthopedic Innovation

Updated Category News Views 42

Foot and Ankle Care Leap at Mercy Medical Mercy Medical Center in Baltimore is shaking things up in the orthopedic world. On August 10, 2026, they pulled the curtain back on the Center for Orthopedic Innovation, a place where the future of foot and ankle care is being molded. Led by renowned figure Dr. Lew Schon, they've crafted a cutting-edge space that’s all about...

Continue Reading
GECU's $4.9B Milestone: Navigating Regulatory Hurdles

Updated Category News Views 49

GECU's Bold Step: Merging with Bank of the Southwest When the gears of the financial world start grinding, there's no room for hesitation. GECU, one of the powerhouses when it comes to credit unions locally in Texas and New Mexico, has just snagged the regulatory green light to merge with the Bank of the Southwest. Talk about making moves—this transition's poised to...

Continue Reading
Taiwan's Economic Surge Driven by AI Innovations and Exports

Updated Category News Views 264

Economic Growth Outlook in Taiwan Taiwan has recently upgraded its economic growth forecast, reflecting its robust performance amid the ongoing AI revolution. As global appetite for AI-driven technology continues to surge, Taiwan is poised to reap substantial benefits. AI-Driven Exports In a remarkable display of economic resilience, Taiwan's exports skyrocketed almost...

Continue Reading
Exceptional Gold Intersections Reported at Keats Trench

Updated Category News Views 111

Major Discoveries in Gold Exploration New Found Gold Corp. (TSXV: NFG) (NYSE-A: NFGC) is thrilled to disclose impressive results from the second phase of channel sampling at Keats Trench as part of its ongoing exploration efforts at the Queensway Project. Highlights from Keats Trench Phase II The company noted exceptional intercepts in its sampling campaign, including...

Continue Reading